The Mammastatin Serum Assay may help identify both women with breast cancer and those at risk to develop breast cancer. We currently are evaluating estrogen and androgen levels in serum from 74 women who developed postmenopausal breast cancer and 148 matched controls. (1998) Correlation between carotenoid concentrations in serum and in normal breast tissues of women with benign breast tumor or breast cancer. There was no association between reported total serum cholesterol levels and breast cancer risk in either pre-menopausal or post-menopausal women. In conclusion, the present results suggest that activin A is expressed at both tissue and serum in postmenopausal women with breast cancer. There did not appear to be an increased risk of breast cancer with different serum levels of PCBs among women who carried m4 genotypes.
Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Prostate-specific antigen in serum of women with breast cancer. Individual serum TCDD is significantly related with breast cancer incidence among women in the SWHS cohort. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Sources of elevated serum androgens in postmenopausal women who develop breast cancer. No significant difference in serum levels was found between the women with breast cancer and the control group. Over the intervening two decades, 240 women in the study who had serum samples later developed breast cancer. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Department of Defense on a study of the predictive value for breastcancer of serum organochlorine levels among occupationally exposed women.
(2004) SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancer. In a study published by Wolff et al in 1993,7 breast cancer was strongly associated with the concentration of DDE in serum. No differences in serum levels of total DDT or HCB were found between oestrogen receptor positive and oestrogen receptor negative patients with breast cancer. Samples were analysed in duplicate in batches that included breast cancer and control samples, together with pooled serum quality control samples. Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Univariate analyses showed that cases and controls had no significant association between serum cholesterol level and BMI and breast cancer. CONCLUSION: Serum c-erbB-2 levels are elevated in approximately one fourth of patients with locally advanced or metastatic breast cancer. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients